Acquisition of Standardized Medicines Belonging Tender

• Country: Brazil
• Summary: Acquisition of Standardized Medicines Belonging to the Groups: 09.B.03.X - other Antianemic Preparations, 09.H.01.B - Hormones of the Posterior Lobe of the Pituitary, 09.H.02.A - Us Corticosteroids...
• BRT Ref No: 132516606
• Deadline: 07 Jan 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 90309/2025
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Object: Electronic Auction - Acquisition of standardized medicines belonging to the Groups: 09.B.03.X - OTHER ANTIANEMIC PREPARATIONS, 09.H.01.B - HORMONES OF THE POSTERIOR LOBE OF THE PITUITARY, 09.H.02.A - CORTICOSTEROIDS FOR SYSTEMIC USE, ISOLATED and 09.H.01.C - HYPOTHALAMIC HORMONES in order to maintain regular supply - SES/DF, uninterruptedly, as well as guarantee assistance to SUS/DF users, according to Annex I of the Notice. UASG code: 926119 Notice from: 12/22/2025 from 08:00 to 12:00 pm and from 1:00 pm to 5:00 pm Proposal Delivery: from 12/22/2025 at 08:00 ALFAEPOETIN, CONCENTRATION 4,000 IU/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity: 10130 VASOPRESSIN, CONCENTRATION 20 IU/ML, PHARMACEUTICAL FORM SOLUTION INJECTABLE Quantity: 8295 VASOPRESSIN, CONCENTRATION 20 IU/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity: 2765 DEXAMETHASONE, DOSAGE 4 MG/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity: 184317 TERLIPRESSIN, ACETATE COMPOSITION, CONCENTRATION 1 MG, PHARMACEUTICAL FORM LYOPHIL POWDER FOR INJECTION Quantity: 4192 TERLIPRESSIN, ACETATE COMPOSITION, CONCENTRATION 1 MG, PHARMACEUTICAL FORM LYOPHIL POWDER FOR INJECTION Quantity: 1397 BETAMETHASONE, ACETATE COMPOSITION, PRESENTATION ASSOCIATED WITH BETAMETHASONE PHOSPHATE, DOSAGE 3MG + 3MG/ML, INJECTABLE USE Quantity: 15040 OCTREOTIDE, DOSAGE 0.1 MG/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity: 5788 OCTREOTIDE, DOSAGE 0.1 MG/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity: 1929 HYDROCORTISONE, ACTIVE PRINCIPLE 100MG, INJECTABLE PRESENTATION Quantity: 84428 HYDROCORTISONE, ACTIVE INGREDIENT 100MG, INJECTABLE PRESENTATION Quantity: 28142 HYDROCORTISONE, ACTIVE INGREDIENT 500MG, INJECTABLE PRESENTATION Quantity: 31627 METHYLPREDNISOLONE, PRINCIPLE ACTIVE SUCCINATE SALT, DOSAGE 500 MG, PRESENTATIONLYOPHILIZED POWDER + DILUENT, INJECTABLE Quantity...
• Documents:

 Tender Notice